Boehringer Ingelheim's Lung Cancer Drug Hernexeos Gains FDA Approval
TL;DR
The US FDA has approved Boehringer Ingelheim's drug Hernexeos for treating advanced non-squamous non-small cell lung cancer in patients who have previously received treatment, based on a study showing significant tumor reduction, with an accompanying diagnostic device approval for patient identification.
Topics:businesshealth#boehringer-ingelheim#fda-approval#health#hernexeos#kinase-inhibitors#lung-cancer
- US FDA approves Boehringer Ingelheim's lung cancer treatment Reuters
- Top German Pharma Boehringer Wins US Approval for Cancer Drug Bloomberg.com
- FDA Grants Accelerated Approval to Zongertinib for Nonsquamous NSCLC With HER2 TKD Mutations OncLive
- Amol Akhade: Zongertinib - A New Targeted Therapy Option for a Rare Molecular Subset of Lung Cancer Oncodaily
- Boehringer Ingelheim breaks into oncology with FDA approval for lung cancer med Hernexeos Fierce Pharma
Want the full story? Read the original reporting
Read on Reuters